SANDEEP PATIL
Bangalore
Summary
Strategic R&D leader with 15 years in oncology and immunology, driving discovery-to-clinic processes in global pharmaceutical settings. Led advancement of seven therapeutic programs, including five in clinical stages. Expert in integrating biology, medicinal chemistry, and regulatory strategy into cohesive plans that enhance decision-making and accelerate timelines, delivering strategic portfolio value through structured governance and milestone planning.
Overview
15
15
years of professional experience
Work History
Group Leader I – Translational Immuno-Oncology & Clinical Pharmacology Sciences
Aurigene Oncology
04.2024 - Current
- Led initiatives for differentiated platforms, including macrophage engagers, ADCs, and multispecific antibodies.
- Drove portfolio discussions on candidate differentiation, milestone planning, and development strategy.
- Supported portfolio governance through candidate nomination and strategic prioritization, ensuring alignment with company goals.
- Partnered with biology, medicinal chemistry, DMPK, toxicology, regulatory affairs, and clinical teams to expedite portfolio execution.
- Managed global collaborations, CRO partnerships, and external scientific engagements to achieve successful project milestones.
- Mentored multidisciplinary teams, enhancing organizational capabilities to improve project delivery and collaboration.
Senior Scientist II
Aurigene Oncology
04.2023 - 03.2024
- Directed development planning for translational biomarker strategy, advancing clinical-stage assets.
- Led external pharmacology and toxicology collaborations, improving project outcomes.
- Executed regulatory submissions by collaborating with cross-functional teams to ensure compliance. through cross-functional execution.
Scientist I–III
Aurigene Oncology
07.2015 - 03.2023
- Facilitated discovery and development of AUR101, AUR103, AUR104, AUR106, and AUR112, enhancing the pipeline of therapeutic candidates.
- Developed translational pharmacology and immune biology capabilities to improve candidate selection processes.
- Conducted comprehensive scientific assessments to support strategic candidate nominations.
- Managed collaborations with global CROs in pharmacology and toxicology.
Visiting Scholar
Genelux Corporation
04.2014 - 04.2015
- Conducted immune monitoring and translational analysis of phase II oncology clinical trial samples of oncolytic vaccinia virus therapy.
Ph.D. Researcher
University of Würzburg
04.2011 - 07.2014
- Engineered recombinant vaccinia virus-based cancer immunotherapies targeting VEGF and CD47, advancing understanding of tumor immunology and immune modulation.
Education
Ph.D. - Oncology & Immunology
University of Würzburg
Germany07-2014
M.Sc. - Virology
National Institute of Virology
Pune06-2009
B.V.Sc. -
Bombay Veterinary College
Mumbai06-2007
Skills
- Translational pharmacology
- 5 clinical-stage assets
- Multiple US FDA IND submissions
- Portfolio governance and candidate nomination leadership
- 2 candidate nomination programs
- Strategic planning across small molecules and biologics
- Platform development
- Global collaborations across biotechnology and pharmaceutical organizations in the United States and Europe
- Cross-functional leadership spanning Biology, Chemistry, DMPK, Toxicology, Regulatory and Clinical Development
- 15 years of pharmaceutical R&D leadership
- Strategic leadership
- Patent Inventor – US20250339404A1
R&D Portfolio Leadership
- AUR101, Phase II, Discovery-to-clinical development support
- AUR103, Phase I, Clinical strategy, translational pharmacology, biomarker leadership
- AUR104, Clinical Stage, Discovery biology leadership
- AUR106, Phase I, Discovery, Candidate differentiation and development strategy
- AUR112, Phase I, Discovery, Translational biomarker and clinical development support
- Immuno-Oncology Program, Candidate Nomination, Portfolio leadership
- Multi-specific Checkpoint Program, Candidate Nomination, Portfolio leadership
- Differentiated Macrophage Engager Platform development, Ongoing
- Differentiated ADC Platform development, Ongoing
Patent And Scientific Recognition
- US20250339404A1 – Inventor.
- AACR, SITC and EORTC-NCI-AACR presentations.
- Received grant from BIRAC (Govt of India) for discovery of trispecific antibody for solid cancer therapy
Timeline
Group Leader I – Translational Immuno-Oncology & Clinical Pharmacology Sciences
Aurigene Oncology
04.2024 - Current
Senior Scientist II
Aurigene Oncology
04.2023 - 03.2024
Scientist I–III
Aurigene Oncology
07.2015 - 03.2023
Visiting Scholar
Genelux Corporation
04.2014 - 04.2015
Ph.D. Researcher
University of Würzburg
04.2011 - 07.2014
Ph.D. - Oncology & Immunology
University of Würzburg
M.Sc. - Virology
National Institute of Virology
B.V.Sc. -
Bombay Veterinary College